Provention Bio, Inc. (PRVB)
$23.895
Rating:
Recommendation:
Neutral
| Symbol | PRVB |
|---|---|
| Price | $23.895 |
| Beta | 2.178 |
| Volume Avg. | 2.09M |
| Market Cap | 2.177B |
| Shares () | - |
| 52 Week Range | 3.185-24.23 |
| 1y Target Est | - |
| DCF Unlevered | PRVB DCF -> | |
|---|---|---|
| DCF Levered | PRVB LDCF -> | |
| ROE | -99.08% | Strong Sell |
| ROA | -54.72% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 33.95% | Neutral |
| P/E | -15.62 | Strong Sell |
| P/B | 13.72 | Strong Buy |
Latest PRVB news
About
Download (Excel)Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.